Unmet Medical Needs in Chronic, Non-Communicable Inflammatory Skin Diseases

June 2022 in “ Frontiers in medicine ”

Hideyuki Ujiie, David Rosmarin, Michael P. Schön, Sonja Ständer, Katharina Boch, Martin Metz, Marcus Maurer, Diamant Thaçi, Enno Schmidt, Connor Cole, Kyle T. Amber, Dario Didona, Michael Hertl, Andreas Recke, Hanna Graßhoff, Alexander Hackel, Anja Schumann, Gabriela Riemekasten, Katja Bieber, Grant Sprow, Joshua Dan, Detlef Zillikens, Tanya Sezin, Angela M. Christiano, Kerstin Wolk, Robert Sabat, Khalaf Kridin, Victoria P. Werth, Ralf J. Ludwig

atopic dermatitis psoriasis urticaria lichen planus hidradenitis suppurativa T cell B cell systemic immunosuppression biomarkers

Studysummary This review discusses the complex causes and treatment challenges of chronic inflammatory skin diseases, emphasizing the need for biomarkers to predict treatment responses; it reports no new clinical results.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

Chronic, non-communicable inflammatory skin diseases affect an estimated 20-25% of the population and include conditions such as atopic dermatitis, psoriasis, urticaria, lichen planus, and hidradenitis suppurativa, with causes ranging from genetic to environmental factors, and autoimmune responses that may be T cell or B cell driven. Despite improvements in diagnosis and treatment, challenges persist, including missed early diagnosis for rarer diseases, adverse events from systemic immunosuppression, unpredictable treatment responses, and the need for biomarkers to tailor individual patient treatments. The document suggests optimism for future advancements in addressing these challenges.

View this study on frontiersin.org →

Discuss this study in the Community →

Research cited in this study

20 / 20 results

Efficacy and Safety of the Oral Janus Kinase Inhibitor Baricitinib in the Treatment of Adults with Alopecia Areata: Phase 2 Results from a Randomized Controlled Study

research Efficacy and Safety of the Oral Janus Kinase Inhibitor Baricitinib in the Treatment of Adults with Alopecia Areata: Phase 2 Results from a Randomized Controlled Study

66 citations , June 2021 in “Journal of The American Academy of Dermatology”

In this phase 2 study, baricitinib at 2 mg and 4 mg doses significantly improved hair regrowth in adults with alopecia areata and ≥50% scalp hair loss compared to placebo, without new safety concerns, although the small sample size limits the results' generalizability.

research Features Associated With Quality of Life Impairment in Hidradenitis Suppurativa Patients

61 citations , April 2021 in “Frontiers in Medicine”

This study found that hidradenitis suppurativa significantly impaired quality of life in German patients, with severity linked to skin and certain extra-cutaneous changes, but not reduced by surgical or conventional medicamentous treatments.

research A Phase 2a Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of the Oral Janus Kinase Inhibitors Ritlecitinib and Brepocitinib in Alopecia Areata: 24-Week Results

138 citations , March 2021 in “Journal of the American Academy of Dermatology”

This study found that treatment with ritlecitinib or brepocitinib was effective in improving scalp hair loss for patients with alopecia areata over 24 weeks compared to placebo.

research Italian Guidelines in Diagnosis and Treatment of Alopecia Areata

37 citations , December 2019 in “Giornale italiano di dermatologia e venereologia”

This Italian guideline discusses the diagnosis and treatment of alopecia areata but reports no new clinical trial results; the authors highlight the need for well-designed studies.

research A Review of Cutaneous Lupus Erythematosus: Improving Outcomes with a Multidisciplinary Approach

26 citations , May 2019 in “Journal of Multidisciplinary Healthcare”

This review explores the epidemiology, clinical subtypes, pathology, psychological impact, and treatment options for cutaneous lupus erythematosus, emphasizing the importance of interdisciplinary collaboration and addressing psychological distress to optimize patient outcomes.

An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis

research An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis

130 citations , February 2018 in “Journal of Investigative Dermatology”

This study found that tofacitinib led to ≥50% hair regrowth in eight out of twelve patients with moderate to severe alopecia areata, suggesting a potential benefit for using JAK inhibitors in treating this condition.

research Nail Changes in Alopecia Areata: An Update and Review

45 citations , January 2018 in “International Journal of Dermatology”

This review explores nail changes associated with alopecia areata, noting their prevalence and impact on appearance and function, but reports no new clinical findings; the authors call for larger controlled trials.

research Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata

196 citations , September 2016 in “JCI insight”

This study explored the effectiveness of the oral JAK1/2 inhibitor ruxolitinib in treating patients with moderate-to-severe alopecia areata, building on prior success with JAK inhibitors in mice, but results are not reported in this abstract.

research Familial Aggregation of Alopecia Areata

295 citations , May 2016 in “Journal of the American Academy of Dermatology”

This review examines the immunological aspects of alopecia areata, focusing on genetic, neuroimmunological, and immune privilege factors, but does not report new clinical findings.

research Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition

701 citations , August 2014 in “Nature medicine”

This study found that JAK inhibitors promote hair regrowth in both mice and human alopecia areata cases by blocking key immune pathways involved in disease development.

research Guidelines for the Management of Vitiligo: The European Dermatology Forum Consensus

281 citations , January 2013 in “British Journal of Dermatology”

Manage vitiligo with treatments, address emotions, and use camouflage techniques.

research Histopathology of Alopecia Areata, Acute and Chronic: Why Is It Important to the Clinician?

43 citations , May 2011 in “Dermatologic Therapy”

This article discusses the phases and histological features of alopecia areata and reports no new clinical findings; the authors emphasize recognizing these phases for accurate diagnosis.

research Quality of Life in Cutaneous Lupus Erythematosus

158 citations , March 2011 in “Journal of the American Academy of Dermatology”

In this study, cutaneous lupus erythematosus was associated with significantly impaired quality of life, particularly affecting emotional well-being, compared to other dermatologic and chronic medical conditions.

research Intralesional Steroids for Alopecia Areata

36 citations , January 2010 in “International Journal of Trichology”

Intralesional steroids can help regrow hair in some alopecia areata patients but have side effects.

research Medium-Dose Prednisolone Pulse Therapy in Alopecia Areata

17 citations , November 2009 in “Dermato-endocrinology”

This study found that a series of three monthly courses of medium-dose prednisolone pulse therapy was effective and well tolerated in most patients with active, multifocal alopecia areata but not in those with totalis/universalis.

research Placebo-Controlled Oral Pulse Prednisolone Therapy in Alopecia Areata

141 citations , February 2005 in “Journal of the American Academy of Dermatology”

In this study, oral prednisolone pulse therapy led to significant hair regrowth in some patients with extensive alopecia areata, whereas no improvement was seen in the placebo group.

research Guidelines for the Management of Alopecia Areata

182 citations , October 2003 in “British Journal of Dermatology”

These guidelines for alopecia areata management, prepared by the British Association of Dermatologists, provide evidence-based treatment recommendations and insights into the condition's epidemiology, diagnosis, and investigation.